GLA-AF, an emulsion-free vaccine adjuvant for pandemic influenza

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Clegg, Christopher H ^a   Roque, Richard ^a   Perrone, Lucy A ^a,e   Rininger, Joseph A ^b   Bowen, Richard ^c   Reed, Steven G ^d  

^a TRIA Bioscience Corp   (United States)

^b CaroGen Corporation   (United States)

^c Department of Environmental and Radiological Health Sciences   (United States)

^d INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOLOGICAL ADJUVANT; INFLUENZA VIRUS HEMAGGLUTININ; LIPID; RECOMBINANT ANTIGEN; RECOMBINANT H5 HEMAGGLUTININ ANTIGEN; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; AQUEOUS SOLUTION; ARTICLE; CONTROLLED STUDY; DRUG DEVELOPMENT; DRUG MANUFACTURE; FEMALE; FERRET; HEMAGGLUTINATION INHIBITION; HEMAGGLUTINATION INHIBITION TEST; IMMUNOGENICITY; IMMUNOSTIMULATION; INFLUENZA A (H5N1); INTERMETHOD COMPARISON; MOUSE; NONHUMAN; PANDEMIC INFLUENZA; VIRUS IMMUNITY; VIRUS LOAD; VIRUS STRAIN;

1,2-DIPALMITOYLPHOSPHATIDYLCHOLINE; ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODY FORMATION; DOGS; DRUG COMBINATIONS; EMULSIONS; FEMALE; FERRETS; HUMANS; IMMUNITY; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; LIPID A; MADIN DARBY CANINE KIDNEY CELLS; MICE; MICE, INBRED C57BL; ORTHOMYXOVIRIDAE INFECTIONS; PANDEMICS; TH1 CELLS;

EID: 84895875776     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0088979     Document Type: Article

References (34)

1. World Health Organization website. Available: http://www.who.int/ influenza/human-animal-interface/H5N1-cumulative-table-archives/en/. Accessed 2014 Jan 23.
2. Lam TT, Wang J, Shen Y, Zhou B, Duan L, et al (2013) The genesis and source of the H7N9 influenza viruses causing human infections in China. Nature. doi: 10.1038/nature12515.
3. Richard M, Schrauwen EJ, de Graaf M, Bestebroer TM, Spronken MI, et al (2013) Limited airborne transmission of H7N9 influenza A virus between ferrets. Nature 501: 560-3.
4. Zhang Q, Shi J, Deng G, Guo J, Zeng X, et al (2013) H7N9 influenza viruses are transmissible in ferrets by respiratory droplet. Science 341: 410-4.
5. Qi X, Qian YH, Bao CJ, Guo XL, Cui LB, et al (2013) Probable person to person transmission of novel avian H7N9 influenza A (H7N9) virus in Eastern China, 2013: epidemiological investigation. BMJ 347: f4752.
6. Galli G, Hancock K, Hoschler K, DeVos J, Praus M, et al (2009) Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc. Natl. Acad. Sci. U S A 106: 7962-7.
7. Banzhoff A, Gasparini R, Laghi-Pasini F, Staniscia, T Durando, P, etal (2009) MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS One 4: e4384.
8. Schwarz TF, Horacek T, Knuf M, Damman H, Roman F, et al.(2009) Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults. Vaccine 27: 6284-90.
9. Leroux-Roels I, Roman F, Forgus S, Maes C, de Boever, F, etal. (2010) Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study. Vaccine 28: 849-57.
10. Vesikari T, Karvonen A, Tilman S, Borkowski A, Montomoli E, et al (2010) Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence. Pediatrics 126: e762-70.
11. Clegg CH, Rininger JA, Baldwin SL. (2013) Clinical vaccine development for H5N1 influenza. Expert Rev Vaccines. 12(7): 767-77.
12. Lippi G, Targher G, Franchini M. (2010) Vaccination, squalene and anti-squalene antibodies: facts or fiction? Eur J Intern Med. 21(2): 70-3.
13. Nohynek H, Jokinen J, Partinen M, Vaarala O, Kirjavainen T, et al (2012) AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS One 7: e33536.
14. Duthie M, Windish H, Fox C, Reed S (2011) Use of defined TLR ligands as adjuvants within human vaccines. Immunol Rev. 239: 178-196.
15. McKeage K, Romanowski B (2011) AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix): a review of its use in the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types. Drugs 71: 465-88.
16. Clegg CH, Roque R, Van Hoeven N, Perrone L, Baldwin SL, et al (2012) Adjuvant solution for pandemic influenza vaccine production. Proc Natl Acad Sci U S A. 109: 17585-90.
17. Anderson R, Fox C, Dutill T, Shaverdian N, Evers T, et al (2010) Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations. Colloids and Surfaces B: Biointerfaces 75: 123-32.
18. Kendal AP, Pereira MS, Skehel JJ (1982) Hemagglutination inhibition. In: Kendal AP, Pereira MS, Skehel JJ, editors. Concepts and procedures for laboratory based influenza surveillance. Atlanta: Centers for Disease Control and Pan-American Health Organization. B17-35.
19. Fox CB, Huynh C, O'Hara MK, Onu A (2013) Technology transfer of oil-in-water emulsion adjuvant manufacturing for pandemic influenza vaccine production in Romania. Vaccine. 31: 1633-1640.
20. O'Hagan DT, Ott GS, De Gregorio E, Seubert A (2012) The mechanism of action of MF59 - an innately attractive adjuvant formulation. Vaccine 30: 4341-8.
21. Galli G, Medini D, Borgogni E, Zedda L, Bardelli M, et al (2009) Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc. Natl. Acad. Sci. USA 106: 3877-82.
22. Khurana S, Verma N, Yewdell JW, Hilbert A, Castellino F, et al (2011) MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci. Transl. Med. 3: 85ra48.
23. Ahmed S, Plotkin S, Black S, Coffman R (2011) Assessing the safety of adjuvanted vaccines. Sci. Transl. Med. 3: 93rv2.
24. Pellegrini M, Nicolay U, Lindert K, Groth N, Della Cioppa G (2009) MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database. Vaccine 27: 6959-6965.
25. Wijnans L, Lecomte C, de Vries C, Weibel D, Sammon C, et al (2013) The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns. Vaccine 31: 1246-54.
26. Kothare SV, Wiznitzer M (2013) Association between H1N1 vaccination and narcolepsy-cataplexy: Flu to sleep. Neurology 80: 1276-7.
27. Dormitzer PR, Galli G, Castellino F, Golding H, Khurana S, et al (2011) Influenza vaccine immunology. Immunol. Rev. 239: 167-77.
28. Kannanganat S, Ibegbu C, Chennareddi L, Robinson H, Amara R (2007) Multiple-cytokine-producing antiviral CD4 T cells are functionally superior to single-cytokine-producing cells. J. Virol 81: 8468-76. (Pubitemid 47242819)
29. McKinstry K, Strutt T, Swain S (2011) Hallmarks of CD4 T cell immunity against influenza. J Intern Med 269: 507-18.
30. Hagen S, Thompson J, Snyder D, Myers K (1997) Analysis of a monophosphoryl lipid A immunostimulant preparation from Salmonella minnesota R595 by high-performance liquid chromatography. J Chromatogr A 767: 53-61. (Pubitemid 27199242)
31. Rallabhandi P, Awomoyi A, Thomas K, Phalipon A, Fujimoto Y, et al (2008) Differential activation of human TLR4 by Escherichia coli and Shigella flexneri 2a lipopolysaccharide: combined effects of lipid A acylation state and TLR4 polymorphisms on signaling. J Immunol 180: 1139-47.
32. Coler RN, Bertholet S, Moutaftsi M, Guderian J, Windish H, et al (2011) Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS One 6: e16333.
33. Orr MT, Fox CB, Baldwin SL, Sivananthan SJ, Lucas E, et al (2013) Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis. J Control Release 172: 190-200.
34. Belser JA, Katz JM, Tumpey TM (2011) The ferret as a model organism to study influenza A virus infection. Dis Model Mech 4: 575-579.